{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:19:08Z","timestamp":1760660348232,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":3547,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1016\/j.rmed.2003.10.004","type":"journal-article","created":{"date-parts":[[2003,12,10]],"date-time":"2003-12-10T08:57:46Z","timestamp":1071046666000},"page":"S10-S19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S4","title":["Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses"],"prefix":"10.1016","volume":"97","author":[{"given":"I","family":"Grzelewska-Rzymowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Malolepszy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"de Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sladek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Zarkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Siergiejko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2003.10.004_BIB1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(94)92770-7","article-title":"CFCs and inhalers","volume":"344","author":"Woodcock","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2003.10.004_BIB2","unstructured":"Aubier M. Air pollution and allergic asthma. Rev Mal Respir 2000;17:159\u201365c."},{"issue":"Suppl. 1","key":"10.1016\/j.rmed.2003.10.004_BIB3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0929-693X(00)88811-9","article-title":"Respiratory distress in pediatric admission and emergency services. Epidemiology and evaluation criteria","volume":"7","author":"Marguet","year":"2000","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.rmed.2003.10.004_BIB4","unstructured":"USA National Institute of Health. NationalHeart, Lung and Blood Institute. NHLBI\/WHO Workshop Report: Global Strategy for Asthma Management and Prevention. Report No. 02-3659, issued January 1995, revised 2002."},{"key":"10.1016\/j.rmed.2003.10.004_BIB5","doi-asserted-by":"crossref","unstructured":"British Thoracic Society. The British Guidelines on Asthma Management. 1995 Review and Position Statement. Thorax 1997;52(Suppl. 1):s1\u201320.","DOI":"10.1136\/thx.52.suppl_1.S1"},{"issue":"Suppl. 1","key":"10.1016\/j.rmed.2003.10.004_BIB6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/jam.1995.8.Suppl_1.S-3","article-title":"CFCs, their replacements, and the ozone-layer","volume":"8","author":"Noakes","year":"1995","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.rmed.2003.10.004_BIB7","unstructured":"Result of co-ordinated review of 1,1,1,2-tetrafluoroethane HFA-134a. CPMP\u2014Meeting of 12\u201313 July 1994."},{"issue":"3","key":"10.1016\/j.rmed.2003.10.004_BIB8","first-page":"375","article-title":"Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy is asthma and rhinitis","volume":"44","author":"Brodgen","year":"1992","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.rmed.2003.10.004_BIB9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1081-1206(10)61893-5","article-title":"Budesonide fatty-acid esterification","volume":"88","author":"Edsbacker","year":"2002","journal-title":"Ann Allergy, Asthma Immunol"},{"issue":"Suppl. 16","key":"10.1016\/j.rmed.2003.10.004_BIB10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows","volume":"6","author":"Quanjer","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2003.10.004_BIB11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1164\/ajrccm\/143.2.323","article-title":"The normal range of diurnal changes in peak expiratory flow rates","volume":"143","author":"Quackenboss","year":"1991","journal-title":"Am Rev Respir Dis"},{"year":"1995","series-title":"nquery advisor user's guide","author":"Elashoff","key":"10.1016\/j.rmed.2003.10.004_BIB12"},{"key":"10.1016\/j.rmed.2003.10.004_BIB13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-5173(99)00137-4","article-title":"Modulation of aerosol clouds produced by pressurised inhalation aerosols","volume":"186","author":"Brambilla","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.rmed.2003.10.004_BIB14","first-page":"1210","article-title":"Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane\u2014beclomethasone extrafine inhalation aerosol), in asthma","volume":"105","author":"Van der Burgt","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl. B","key":"10.1016\/j.rmed.2003.10.004_BIB15","first-page":"S29","article-title":"Clinical efficacy and safety of fluticasone propionate 250\u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma","volume":"94","author":"Tonnel","year":"2000","journal-title":"Respir Med"},{"issue":"Suppl. B","key":"10.1016\/j.rmed.2003.10.004_BIB16","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0954-6111(00)80148-1","article-title":"Clinical efficacy and safety of fluticasone propionate 1mg per day administered via a HFA-134a pressurized metered dose inhaler to patients with moderate to severe asthma","volume":"94","author":"Perruchoud","year":"2000","journal-title":"Respir Med"},{"issue":"Suppl. B","key":"10.1016\/j.rmed.2003.10.004_BIB17","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0954-6111(00)80149-3","article-title":"Clinical efficacy and safety of fluticasone propionate 1mg twice daily administered via a HFA-134a pressurized metered dose inhaler to patients with severe asthma","volume":"94","author":"Ayres","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2003.10.004_BIB18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1742-1241.1997.tb09618.x","article-title":"Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate","volume":"51","author":"Dahl","year":"1997","journal-title":"Br J Clin Pract"},{"key":"10.1016\/j.rmed.2003.10.004_BIB19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/rmed.2000.1025","article-title":"Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800\u03bcgday\u22121) versus HFA-fluticasone propionate (1000\u03bcgday\u22121) in patients with asthma","volume":"95","author":"Aubier","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2003.10.004_BIB20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000196686","article-title":"Therapeutic equivalence of a novel HFA-134a containing metered dose inhaler and the conventional CFC inhaler (berodual\u00ae) for the delivery of a fixed combination of fenoterol\/ipratropium bromide","volume":"64","author":"Maesen","year":"1997","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2003.10.004_BIB21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/rmed.1999.0631","article-title":"Equivalence of hydrofluoroalkane (HFA) and chlorofluorocarbons (CFC) formulation of inhaled beclomethasone (letters to the Editor)","volume":"94","author":"Lipworth","year":"2000","journal-title":"Respir Med"},{"issue":"13","key":"10.1016\/j.rmed.2003.10.004_BIB22","first-page":"220","article-title":"Beclomethasone dipropionate given to adult asthmatics through a new spacer device","volume":"4","author":"Girbino","year":"1996","journal-title":"Adv Therapy"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611103003627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611103003627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:05:38Z","timestamp":1760609138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611103003627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":22,"alternative-id":["S0954611103003627"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2003.10.004","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2003,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2003.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}